#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Network Open.
Click to read this study in The Lancet Oncology.
1. A five-year extension of anastrozole treatment was shown not to provide additional benefit compared to a two-year extension in ...
Click to read the study in the European Journal of Cancer.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.